Status:
UNKNOWN
Peripheral Primitive Fibromatosis
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Conditions:
Peripheral Primitive Fibromatosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
It's a monitoring study. The aim is to assess the progression free survival up to 3 years. Patients are not treated until progression. Search for scalability predictive factors and registration of tre...
Eligibility Criteria
Inclusion
- Peripheral primitive fibromatosis
- Adults patients
- Peripheral primitive fibromatosis proved by biopsy
- Peripheral primitive fibromatosis R2 resected for which monitoring is decided
- MRI realized before inclusion
- Patient information and informed consent signed
Exclusion
- Local recur
- Head and neck topography
- Primitive fibromatosis R0 or R1 resected
- Specific medical treatment of fibromatosis
- Patient already included in an other clinical trial with an experimental molecule
- Persons deprived of liberty
- Impossibility to submit to the trial's medical follow-up for psychological, geographical or socials reasons
- Previous history of cancer
- Counter indication to the realization of an MRI
Key Trial Info
Start Date :
May 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01801176
Start Date
May 1 2012
End Date
May 1 2018
Last Update
June 9 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Gustave Roussy
Villejuif, Val de Marne, France, 94805